NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy .
Gynecol Endocrinol. 2013 Dec;29(12):1005-14. doi: 10.3109/09513590.2013.813468. Epub 2013 Sep 25.
The aim of this meta-analysis was to evaluate the efficacy and safety of two bisphosphonates (alendronate and zoledronate) in the treatment of postmenopausal osteoporosis. The incidence of fractures was considered as primary endpoint. Only randomized trials with a follow-up period of 1 year or more were included in this systematic review and meta-analysis. We excluded studies that included patients with secondary osteoporosis especially in relation to therapy with corticosteroids or other drugs or diseases known to affect bone mineral density. Studies published as subgroup analysis, extension studies, economic evaluations, and comparisons with active control were excluded. The methodological quality of controlled clinical trials that met these inclusion criteria was evaluated. No studies were excluded from analysis due to lack of quality. The risk ratio of hip, vertebral and wrist fractures for alendronate were 0.61 [95% confidence interval (CI) 0.40-0.93], 0.54 (95% CI 0.44-0.66) and 0.65 (95% CI 0.33-1.25), respectively. Zoledronate risk ratio was 0.62 (95% CI 0.46-0.82) and 0.38 (95% CI 0.22-0.67) for hip and vertebral fractures, respectively.
本荟萃分析旨在评估两种双膦酸盐（阿仑膦酸钠和唑来膦酸）治疗绝经后骨质疏松症的疗效和安全性。骨折发生率被视为主要终点。只有随访时间为 1 年或以上的随机试验被纳入本系统评价和荟萃分析。我们排除了那些包括继发性骨质疏松症患者的研究，特别是与皮质类固醇或其他药物治疗或已知影响骨密度的疾病有关的患者。排除了作为亚组分析、扩展研究、经济评估以及与活性对照比较的研究。评估了符合这些纳入标准的对照临床试验的方法学质量。由于缺乏质量，没有研究被排除在分析之外。阿仑膦酸钠髋部、椎体和腕部骨折的风险比分别为 0.61[95%置信区间（CI）0.40-0.93]、0.54（95%CI 0.44-0.66）和 0.65（95%CI 0.33-1.25）。唑来膦酸髋部和椎体骨折的风险比分别为 0.62（95%CI 0.46-0.82）和 0.38（95%CI 0.22-0.67）。
